Insights from ASCO 2025, including anticipated presentations, key takeaways, and how new research in metastatic breast cancer ...

US pharma giant Pfizer will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 ...

Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in ...

CEO John Houston highlighted the company's progress in advancing Vepdegestrant (VEPDEG), noting it recently achieved positive pivotal data from the VERITAC-2 study in ESR1 mutant breast cancer.

Reported positive topline data for VERITAC-2, the Phase 3 pivotal 2L+ trial of monotherapy vepdegestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative ...

Shares of Arvinas tumbled 53% to $8.30 on March 11 after it reported results from the Veritac-2 Phase 3 trial of vepdegestrant. Arvinas and Pfizer have said the results were positive and that the ...

– Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuroscience program with ARV-102 ...

Arvinas, Inc. reported positive topline results from its Phase 3 VERITAC-2 trial for vepdegestrant, supporting global regulatory filings aimed at treating metastatic breast cancer. The company ...

Despite reporting positive topline results from the Phase 3 VERITAC-2 trial and presenting promising data for its neuroscience program, the clinical-stage biotechnology firm’s decision to re ...